Natera

Step 1: Collect a baseline tumor sample from the patient.

Step 2: Perform whole-exome sequencing on the tumor sample to identify unique tumor mutations.

Step 3: Design a personalized Signatera assay targeting the identified mutations.

Step 4: Monitor ctDNA levels in the patient's blood during and after treatment to detect MRD and recurrence.

Step 1: Collect a blood sample from the transplant recipient.

Step 2: Analyze the sample to measure the amount of donor-derived cell-free DNA (dd-cfDNA).

Step 3: Compare the dd-cfDNA levels to established thresholds.

Step 4: Alert clinicians to potential rejection events based on elevated dd-cfDNA levels, prompting further investigation.

Step 1: Collect a blood or saliva sample from the individual.

Step 2: Analyze the sample to detect specific genetic variants associated with various inherited conditions.

Step 3: Determine carrier status for each screened condition.

Step 4: Provide results to the individual and/or their healthcare provider for informed reproductive decision-making.

Step 1: Collect tumor tissue at time of surgery.

Step 2: Analyze tissue to identify patient-specific mutations.

Step 3: Create a personalized Signatera assay.

Step 4: Use blood samples to monitor the presence of ctDNA to assess risk of recurrence and inform treatment decisions.